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Abstract
Background:  Ulcerative  colitis  (UC)  is  a  multifactorial  and  polygenic  disease.  Interleukin-22  (IL-
22) is  an  immunomodulatory  cytokine  that  belongs  to  the  IL-10  family.  Currently,  some  IL-22
polymorphisms  have  been  associated  with  inﬂammatory  processes  such  as  rheumatoid  arthritis
and psoriasis  vulgaris,  but  there  are  no  studies  on  UC.
Aim: The  aim  of  this  work  was  to  study  the  frequency  of  polymorphisms  of  IL-22  in  Mexican
patients with  UC.
Methods:  We  studied  a  total  of  199  Mexican  patients  with  conﬁrmed  UC  and  697  healthy  con-
trols. All  individuals  were  born  in  Mexico,  at  least  three  family  generations  earlier.  A  blood
sample was  obtained  from  the  UC  patients  and  healthy  controls  in  order  to  perform  DNA
extraction and  then  to  determine  the  frequency  of  IL-22  polymorphisms  (rs2227485,  rs2272478,
rs2227491).
Results: No  statistical  signiﬁcance  was  found  in  the  gene  and  genotype  frequencies  of  three
SNPs of  IL-22  (rs2227485,  rs2272478,  rs2227491)  between  the  UC  patients  and  healthy  controls.
No association  was  found  between  those  IL-22  SNPs  and  clinical  features  of  UC.
Conclusions:  There  was  no  association  between  IL-22  SNPs  (rs2227485,  rs2272478,  rs2227491)
and the  development  of  UC  in  a  Mexican  population.
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Resumen
Antecedentes:  La  colitis  ulcerosa  (CU)  es  una  enfermedad  multifactorial  y  poligénica.  La
interleucina  (IL)  22  es  una  citocina  inmunomoduladora  que  pertenece  a  la  familia  de  IL-10.
Actualmente,  algunos  polimorﬁsmos  de  la  IL-22  han  sido  asociados  con  procesos  inﬂamatorios,
como artritis  reumatoide  y  psoriasis  vulgar,  sin  embargo,  no  hay  estudios  en  pacientes  con  CU.
Objetivo:  El  objetivo  del  presente  trabajo  es  estudiar  la  frecuencia  de  polimorﬁsmos  de  la  IL-22
en pacientes  con  CU.
Métodos:  Se  estudió  a  199  pacientes  mexicanos  con  diagnóstico  conﬁrmado  de  CU  y  697  con-
troles sanos.  Todos  los  individuos  de  estudio  nacieron  en  México,  al  igual  que  sus  últimas  3
generaciones.  Se  obtuvieron  muestras  de  sangre  de  cada  individuo  y  se  extrajo  ADN;  ﬁnalmente,
se determinó  la  frecuencia  de  polimorﬁsmos  en  la  IL-22  (rs2227485,  rs2272478,  rs2227491).
Resultados:  No  se  encontró  diferencia  signiﬁcativa  en  la  frecuencia  del  gen  y  genotipo  de  los
SNP en  la  IL-22  (rs2227485,  rs2272478,  rs2227491)  entre  pacientes  con  CU  y controles  sanos.
No se  encontró  asociación  entre  los  SNP  de  la  IL-22  y  las  características  clínicas  de  la  CU.
Conclusiones:  Ausencia  de  asociación  entre  los  SNP  de  la  IL-22  (rs2227485,  rs2272478,
rs2227491)  y  el  desarrollo  de  CU  en  población  mexicana.
© 2016  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Ulcerative  colitis  (UC)  is  a  multifactorial  disease  of  unknown
etiology.  It  is  considered  a  polygenic  disorder  that  interacts
with  immunologic  and  environmental  factors,  leading  to  a
chronic  and  relapsing  colonic  inﬂammation  characterized  by
an  aberrant  immune  response.1 The  Genome-Wide  Associa-
tion  Studies  (GWAS)  of  UC  have  identiﬁed  more  than  25,000
possible  single  nucleotide  polymorphisms  (SNP)  for  inﬂam-
matory  bowel  disease  (IBD)  in  susceptible  regions  on  several
chromosomes  such  as  1,  3,  4,  5,  6,  7,  10,  12,  14,  16,  19,
and  X.2,3 It  is  established  that  mucosal  inﬂammation  is  trig-
gered  by  various  cytokines  produced  by  different  pathways,
such  as  the  Th1,  Th2,  and  recently  the  Th17  immunological
response.4
IL-22  is  a  16.7  KDa  immunomodulatory  cytokine  primar-
ily  produced  by  activated  T  cells  and  natural  killer  cells.  It
belongs  to  the  IL-10  family,  which  also  includes  IL-19,  IL-
20,  IL-24,  IL-26,  IL-28,  and  IL-29.5 This  cytokine  acts  as  an
effector  of  the  Th17  pathway  in  response  to  IL-23  with  pro-
inﬂammatory  and  anti-inﬂammatory  properties  that  may
be  implicated  in  the  pathogenesis  of  IBD.  A  previous  study
reported  an  increased  gene  expression  of  IL-22  in  the  mucosa
from  rectal  biopsies  of  patients  with  active  UC.6 The  IL-
22  gene  is  a  5.3  Kb  region  located  in  the  12q15  loci  of
the  chromosome  12,  close  to  the  genes  encoding  IFN- and
IL-26.7
Currently,  some  IL-22  polymorphisms  have  been  asso-
ciated  with  inﬂammatory  processes,  such  as  rheumatoid
arthritis,8 psoriasis  vulgaris,9 multiple  sclerosis,10 asthma,11
fungal-bacterial  infections,  and  mice  models  of  IBD  infected
with  Citrobacter  rodentium.12 There  are  no  previous  stud-
ies  that  evaluate  the  role  of  IL-22  SNPs  in  patients  with  UC.
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phus,  the  aim  of  this  study  was  to  determine  the  frequency
f  IL-22  SNPs  (rs2227485,  rs2272478,  rs2227491)  in  Mexican
atients  with  UC.
aterial and methods
atients  and  controls
atients:  One  hundred  ninety-nine  Mexican  patients  with
iagnosis  of  UC  conﬁrmed  by  histology  were  studied.  These
atients  were  recruited  from  the  Inﬂammatory  Bowel  Dis-
ase  Clinic  at  the  Instituto  Nacional  de  Ciencias  Médicas
 Nutrición  Salvador  Zubiran  in  Mexico  City.  None  of  the
articipants  had  a family  history  of  IBD.
Both  demographic  and  clinical  information  were  obtained
ia  interview  and  from  medical  records.  The  demographic
nd  clinical  variables  considered  in  the  analysis  were:  cur-
ent  age,  UC  duration,  extension  of  disease  (pancolitis,  left
olitis,  or  distal  colitis),  presence  of  extraintestinal  man-
festations  (EIMs),  clinical  course  of  disease,  response  to
edical  treatment,  and  the  presence  of  procto-colectomy.
he  clinical  course  of  disease  was  deﬁned  as:  active  then
nactive  (ﬁrst  episode  followed  by  a  long-term  remission  for
ore  than  5  years),  intermittent  (fewer  than  2  relapses  per
ear),  and  chronic  activity  (persistent  activity  despite  medi-
al  treatment).  Response  to  medical  treatment  was  cate-
orized  as  follows:  favorable,  steroid-dependent  (relapse
hen  prednisone  was  tapered  below  15  mg/day  or  3  months
fter  suspending  the  steroid);  steroid-resistant  (persistent
ctivity  with  prednisone  of  at  least  0.5  mg/kg/day);  immune
odulator-resistant  (lack  of  steroid  sparing  with  azathio-
rine  dose  of  at  least  2  mg/kg/day  for  more  than  3 months).
8 J.K.  Yamamoto-Furusho  et  al.
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Table  1  Demographic  and  clinical  characteristics  of
patients  with  ulcerative  colitis.
Sex  (male/female)  108/91
Age (years)  (mean  ±  SD)  31.5  ±  14
Duration  of  the  disease  (years)  12.34
Extension  of  the  disease  (%)
Pancolitis  67.8
Distal colitis 32.2
Extraintestinal  manifestation  (%)
Present 32.6
Absent  67.3
Clinical  course  of  the  disease  (%)
Active  then  inactive  42
Intermittent  30
Persistent 28
Treatment  response  (%)
Favorable  67.8
Steroid-dependent  20.6
Steroid-resistant  7.5
Immunomodulator-resistant  4
Colectomy  (%)
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Healthy  controls:  Six  hundred  ninety-seven  healthy  and
nrelated  individuals  that  were  born  in  Mexico,  as  were  their
ast  two  generations.  The  individuals  had  no  previous  history
f  any  autoimmune  disease.
thical  considerations
his  study  was  carried  out  according  to  the  principles  in  the
eclaration  of  Helsinki.  The  Ethics  and  Research  Committee
f  our  hospital  approved  the  present  study  and  all  partici-
ants  signed  a  written  statement  of  informed  consent.
lood  sampling  and  genotyping
 3-ml  venous  blood  sample  was  obtained  from  each  par-
icipant  using  a  vacutainer  blood  collection  tube  with  4%
DTA.
DNA  extraction  was  performed  from  mononuclear  cells
hrough  a  non-enzymatic  method,  according  to  Lahiri  and
urnberger.13 DNA  quantiﬁcation  was  done  with  an  ND-
000  spectrophotometer  at  a  280  nm  wavelength.  Finally,
hree  SNPs  (rs2227485,  rs2272478,  rs2227491)  of  the  IL-22
ene  were  genotyped  using  exonuclease  TaqMan  genotyping
ssays  on  an  ABI  Prism  7900  HT  Fast  Real-Time  PCR  system
Applied  Biosystems,  Foster  City,  CA,  USA).
tatistical  analysis
he  present  work  is  a  case-control  study  and  the  statis-
ical  analysis  was  computed  with  IBM  SPSS  18.0  software.
or  each  one  of  the  groups  (controls  and  patients),  the
ardy-Weinberg  equilibrium  of  the  IL-22  polymorphisms  was
nalyzed  using  the  chi-square  test.  The  association  analysis
or  the  frequency  of  a  present  locus  was  evaluated  with  a
 ×  2  contingency  table  and  the  Pearson’s  chi-square  test.
omparisons  of  allele  frequencies  between  subgroups  were
erformed  using  the  EPI-INFO  statistical  package  (Version
.0).  Signiﬁcance  was  set  at  a  p  <  0.05.
esults
emographic  and  clinical  features
f  the  199  UC  patients,  54%  were  women  and  46%  were  men
ith  a  mean  age  at  diagnosis  of  31.5  ±  14  years.  In  the
ontrol  group,  51%  were  women  and  49%  were  men,  with  a
ean  age  of  35  ±  14  years.
Regarding  the  clinical  features,  the  mean  duration  of  dis-
ase  was  12.34  years;  67.8%  of  the  patients  had  pancolitis,
2.2%  presented  with  extraintestinal  manifestations,  and
5.1%  had  a  proctocolectomy.  The  clinical  course  of  disease
as  distributed  as  follows:  42%  of  the  patients  had  active
isease  and  then  long-term  remission;  30%  had  intermit-
ent  activity,  and  28%  had  continuous  or  persistent  activity.
he  response  to  medical  treatment  was  favorable  in  67.8%
f  the  patients;  20.6%  were  steroid-dependent;  7.5%  were
teroid-resistant,  and  4%  were  thiopurine-resistant  as  shown
n  Table  1.
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ePresent  15.1
Absent  84.9
L-22  gene  polymorphisms
he  allele  frequency  for  the  rs2272478  SNP  was  89%  for  allele
 in  both  groups,  with  no  statistical  difference.  With  respect
o  the  rs2227485  SNP,  the  frequency  for  allele  C  was  46%  in
he  control  group  and  50%  in  the  UC  patients,  and  in  regard
o  the  rs2227491  SNP,  the  frequency  of  allele  A  was  45  vs
8%  in  the  healthy  control  group  as  shown  in  Table  2.
iscussion
he  ﬁnding  of  the  present  study  was  that  there  was  no
ssociation  between  3  polymorphisms  of  the  IL-22  gene
rs2227485,  rs2272478,  rs2227491)  and  the  development  of
C  in  Mexican  patients.  In  Western  and  Northern  Euro-
ean  populations,  there  are  27  polymorphisms  identiﬁed
n  the  IL-22  gene  that  have  been  associated  with  a  num-
er  of  illnesses,  such  as  malaria  and  autoimmune  diseases.
evertheless,  it  is  important  to  mention  that  this  is  the
rst  study  performed  on  UC  patients,  In  contrast,  other
tudies  have  found  an  association  between  IL-22  polymor-
hisms  and  psoriasis  vulgaris,14 hepatitis  C  virus  infection,15
nd  mucosa-associated  lymphoma  of  T  cells.16,17 Although
he  selection  of  polymorphisms  evaluated  in  the  present
tudy  was  based  on  immunologic  and  etiopathologic  mech-
nisms  associated  with  psoriasis  vulgaris,14 the  evaluation
f  only  3  IL-22  SNPs  is  a  weakness  of  this  study  that
ould  possibly  lead  to  further  research  with  other  poten-
ial  polymorphisms  reported  in  hepatitis,  colonic  cancer,  and
ymphoma.15--17The  lack  of  association  of  IL-22  SNPs  and  UC
n  Mexicans  patients  does  not  rule  out  the  potential  role  of
ther  SNPs  of  IL-22  reported  in  the  above-mentioned  dis-
ases;  in  IBD,  IL-22  has  the  role  of  a  cytokine  with  both
Genetic  polymorphisms  of  interleukin-22  in  patients  with  ulcerat
Table  2  Allele  and  genotype  frequency  of  IL-22  gene
polymorphisms.
SNP  UC  Controls  p  value
rs2272478  n  =  199  n  =  697
Allele  n  (%)  n  (%)  0.81
A 355  (89)  620  (89)
G 43  (11)  156  (11)
Genotypes  n  (%)  n  (%)
AA  156  (78)  546  (79)  0.95
AG 43  (22)  142  (20)  0.95
GG 0  (0) 7  (1) 0.69
rs2227485  n  =  199 n  =  697
Allele  n  (%) n  (%) 0.15
C 199  (50)  639  (46)
T 199  (50)  751  (54)
Genotypes  n  (%)  n  (%)
CC  45  (23)  135  (19)  0.30
CT 109  (55)  369  (53)  0.62
TT 45  (22) 195  (28)  0.13
rs2227491  n  =  199  n  =  697
Allele  n  (%)  n  (%)  0.19
A 192  (48)  619  (45)
G 206  (52)  771  (55)
Genotypes  n  (%)  n  (%)
AA  41  (21)  126  (18)  0.43
AG 110  (55)  367  (53)  0.53
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SNP: single nucleotide polymorphism; UC: ulcerative colitis.
pro-inﬂammatory  and  anti-inﬂammatory  effects,  depend-
ing  on  the  type  of  tissue  target.  A  previous  paper  reported
that  IL-22  has  an  anti-inﬂammatory  role  in  an  IBD  animal
model,  since  the  infusion  of  anti  IL-22  proteins  delayed
epithelial  restoration.18 Another  study  found  an  increased
expression  of  the  IL-22  gene  in  rectal  biopsies  from  patients
with  active  UC,  compared  with  UC  in  remission  and  controls
without  inﬂammation.  It  has  been  demonstrated  that  IL-22
participates  in  the  maintenance  of  the  epithelial  barrier  by
inducing  the  expression  of  genes  regulating  proliferation,
wound  healing,  apoptosis,  and  tight  junctions.  It  also  par-
ticipates  in  the  production  of  mucins  such  as  MUC1,  3,  10,
and  13  and  innate  antimicrobials  peptides  such  as  defensins,
Reg  family  molecules,  and  S100  proteins.18
The  IL-22  receptors  include  IL-22R1  and  IL-10R2,  which
are  heterodimeric  proteins  with  speciﬁc  distribution  in  kera-
tinocytes,  hepatocytes,  and  enterocytes,19,20 but  not  in
immune  cells.  Thus  Th17  cells  use  IL-22  to  communicate
only  with  epithelial  and  stromal  cells.  Signaling  transduc-
tion  of  IL-22R1  activates  the  MAPK,  STAT1,  STAT3,  and  STAT5
pathways  through  a  Jak1/Tyk2  kinase  that  stimulates  the
production  of  antimicrobial  agents  and  tissue  repair  by
inducing  proliferation  and  inhibiting  apoptosis.  Although  IL-
22  might  have  proinﬂammatory  properties,  studies  have
shown  that  it  has  a  protective  role  in  the  liver,21 gut,18 and
myocardium.22 The  presence  of  IL-22  and  its  receptors  has
been  described  all  along  the  gastrointestinal  tract,  includ-
ing  the  oral  cavity,  salivary  glands,  esophagus,  stomach,  and
colon.  The  negative  regulation  of  IL-22  is  mediated  by  trans-
forming  growth  factor  beta,  so  even  when  it  is  necessary  forive  colitis  89
H17  differentiation,  it  can  also  act  as  an  inhibitor  of  IL-
2  production  through  the  binding  of  IRF4  to  the  promoter
egion  of  the  IL-22  gene.
Interestingly,  the  inﬂuence  of  some  of  the  genetic  fac-
ors  may  have  a  geographic  distribution.  In  other  words,  one
peciﬁc  SNP  may  predispose  to  IBD  in  a  given  ethnic  group,
hereas  in  a  different  group,  it  may  neither  predispose  to
or  protect  against  IBD.23--25 In  the  Mexican  population,  the
nﬂammatory  cytokine  polymorphism,  IL-15  rs2254514  SNP,
as  associated  with  a  decreased  risk  of  UC  (OR  =  0.62,
 =  0.014)  and  the  IL-15  (rs2254514)  genotype  CC  was  associ-
ted  with  early  age  at  diagnosis  of  UC  (OR  =  3.67,  p  =  0.03).26
n  the  instance  of  IL-1, the  rs16944  SNP  was  associated  with
he  presence  of  steroid  dependence  in  UC  Mexican  patients
OR  =  4.09,  p  =  0.008).27
On  the  other  hand,  several  SNPs  of  anti-inﬂammatory
ytokines  belong  to  the  IL-10  family,  such  as  the  SNPs  of  IL-
0  rs2981573  (p  =  0.017,  OR  =  0.55,  95%  CI  =  -0.33-0.93),  IL-20
s2232360  (p  =  0.017,  OR  =  0.55,  95%  CI  =  0.33-0.93),28 IL-19
s2243188  (p  =  0.018,  OR  =  0.53,  95%  CI  =  0.32-0.86),  and  IL-
9  rs2243193  (p  =  0.006,  OR  =  0.48,  95%  CI  =  0.29-0.80)  and
ave  been  shown  to  have  a protective  role  in  UC.29
In  conclusion,  there  was  no  association  between  IL-22
NPs  and  the  development  of  UC  in  the  Mexican  population.
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